Overview

Price chart · mood · technical indicators

SNY

Sanofi ADRstock Healthcare

Drug Manufacturers - General

$46.0813.30%Current Market Mood:Bearish

Market Mood

Price Range (1Y)

$43.32$54.75

Current: $46.08

Market Comparison

vs Healthcare Sector & Drug Manufacturers - General Industry

SNY

-13.30%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - General

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio19.86Forward 9.19

EPS (TTM)$2.32-11.7% YoY

Profit margin16.0%HEALTHCARE

Market cap$110.40BLarge cap

Wall Street coverage

$55.90median target· current $49.33 (+13.3%)10 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 9.19
PEG ratio: 4.00
P/B: 1.31
P/S (TTM): 2.33
EV/EBITDA: 12.92

Profitability & growth

ROE (TTM): 6.6%
Operating margin: 20.0%
Revenue growth YoY: 6.0%
Dividend yield: 0.0%
Beta: 0.32

Last earnings

Apr 23, 2026 · Estimate $1.05 · Reported $1.10

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Sanofi ADR

Company profile

Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 46, AVENUE DE LA GRANDE ARMEE, PARIS
Fiscal year end: December
Latest quarter: Mar 31, 2026

Market cap$110.40B

Shares outstanding$2.40B

52W high$53.36

52W low$43.32

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

SNY

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Sanofi invests $294M to expand AI Center of Excellence in Toronto and accelerate innovation for patients

Sanofi SA Stock (SNY) Moved Down by 5.57% on May 4: What Investors Need To Know

Sanofi Stock Slips as Traders Brace for Quiet Years

Vanessa Clemendot, Sanofi: Embracing a New Supply Chain Era

Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings

Sanofi’s Oral Venglustat Designated for Type 3 Gaucher Disease Neurological Issues

M&T Bank Corp Sells 402,012 Shares of Sanofi $SNY

Morgan Stanley Downgrades Sanofi (NASDAQ:SNY) to Equal Weight

Merck KgaA's New CEO Kai Beckmann Takes Charge As Belén Garijo Becomes Sanofi CEO

Sanofi Appoints Belén Garijo as CEO | PharmExec

Sanofi Officially Appoints Belén Garijo as Chief Executive Officer Following Shareholder Vote

Why It Might Not Make Sense To Buy Sanofi (EPA:SAN) For Its Upcoming Dividend

Press Release: Annual General Meeting of April 29, 2026 -

Sanofi appoints Belén Garijo as CEO effective May 1

Sanofi Raises €2.3 Billion in Multi-Tranche Euro Bond Offering

Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes

[6-K] Sanofi Current Report (Foreign Issuer) | SNY SEC Filing - Form 6-K

A Look At Sanofi (ENXTPA:SAN) Valuation After Strong Q1 2026 Results And Key Drug Milestones

SANOFI : Bernstein reiterates its Buy rating

Garijo starts as Sanofi CEO with window to ease reliance on Dupixent

About Sanofi ADR

Classification

Company profile

SNY

Market Comparison

SNY Market Analysis

Overview

SNY

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Sanofi invests $294M to expand AI Center of Excellence in Toronto and accelerate innovation for patients

Sanofi SA Stock (SNY) Moved Down by 5.57% on May 4: What Investors Need To Know

Sanofi Stock Slips as Traders Brace for Quiet Years

Vanessa Clemendot, Sanofi: Embracing a New Supply Chain Era

Sanofi's (EPA:SAN) Conservative Accounting Might Explain Soft Earnings

Sanofi’s Oral Venglustat Designated for Type 3 Gaucher Disease Neurological Issues

M&T Bank Corp Sells 402,012 Shares of Sanofi $SNY

Morgan Stanley Downgrades Sanofi (NASDAQ:SNY) to Equal Weight

Merck KgaA's New CEO Kai Beckmann Takes Charge As Belén Garijo Becomes Sanofi CEO

Sanofi Appoints Belén Garijo as CEO | PharmExec

Sanofi Officially Appoints Belén Garijo as Chief Executive Officer Following Shareholder Vote

Why It Might Not Make Sense To Buy Sanofi (EPA:SAN) For Its Upcoming Dividend

Press Release: Annual General Meeting of April 29, 2026 -

Sanofi appoints Belén Garijo as CEO effective May 1

Sanofi Raises €2.3 Billion in Multi-Tranche Euro Bond Offering

Sanofi’s Tzield gets expanded FDA approval for early-stage type 1 diabetes

[6-K] Sanofi Current Report (Foreign Issuer) | SNY SEC Filing - Form 6-K

A Look At Sanofi (ENXTPA:SAN) Valuation After Strong Q1 2026 Results And Key Drug Milestones

SANOFI : Bernstein reiterates its Buy rating

Garijo starts as Sanofi CEO with window to ease reliance on Dupixent

About Sanofi ADR

Classification

Company profile

SNY

Market Comparison